Business Context and Reporting Period
This Form 8-K was filed by Lexaria Bioscience Corp. on November 18, 2020, reporting material events occurring on that date. The company, incorporated in Nevada with principal offices in Kelowna, BC, Canada, announced significant restructuring of its cannabis-related technology agreements involving its subsidiaries Lexaria CanPharm ULC and Lexaria Hemp Corp.
Key Financial Metrics and Transaction Details
The filing details a specific asset purchase agreement (APA) and a new licensing arrangement rather than standard periodic financial results. Key transaction values include:
- Asset Sale Consideration: Total consideration for the sale of DehydraTECH rights for products with 0.3% or greater THC includes $350,000 in cash, $1,500,000 in share equity, and a $2,000,000 promissory note bearing 10% annual interest.
- Anticipated Closing: November 30, 2020.
- Licensing Fees: A new multi-product license agreement for CBD products (0.29% or less THC) involves certain usage fees, though specific amounts are not disclosed in this text.
The filing text does not provide clear values for the company's overall revenue, profit, cash flow, margins, total debt, or liquidity position as of the reporting date.
Material Changes Versus Prior Period
The primary material change is the termination of previous agreements and the execution of new ones:
- Termination: The technology license and joint venture agreements between Lexaria Hemp Corp. and Hill Street Beverage Company Inc., originally executed on July 23, 2019, were mutually terminated.
- Asset Divestiture: Lexaria CanPharm ULC is selling its rights as licensee and licensor for DehydraTECH technology associated with high-THC products (0.3% or greater) to Hill Street.
- New Licensing Structure: A new global non-exclusive license was established for Hill Street to produce CBD-infused products (0.29% or less THC) using DehydraTECH for a ten-year period.
Outlook, Management Commentary, and Risks
Management commentary indicates a strategic shift in how the company monetizes its DehydraTECH technology. Lexaria CanPharm will retain its Health Canada cannabis license and licensed facility to continue research and maintain shareholdings in third-party companies. Additionally, CanPharm will receive a limited license from Hill Street to use DehydraTECH for limited THC products outside of Canada and the US.
The filing does not explicitly list new risks or contingencies beyond the standard obligations of the new agreements. The success of the transaction is contingent on the anticipated closing date of November 30, 2020.
Investor Verification Checklist
- Verify the closing of the asset purchase agreement on or before November 30, 2020.
- Confirm the valuation and terms of the $1,500,000 share equity received from Hill Street.
- Review the specific terms and repayment schedule of the $2,000,000 promissory note.
- Assess the impact of the terminated joint venture on future revenue streams from high-THC products.
- Clarify the specific "usage fees" associated with the new CBD license agreement.